152 related articles for article (PubMed ID: 36729457)
1. Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers.
Diplas BH; Ptashkin R; Chou JF; Sabwa S; Foote MB; Rousseau B; Argilés G; White JR; Stewart CM; Bolton K; Chalasani SB; Desai AM; Goldberg Z; Gu P; Li J; Shcherba M; Zervoudakis A; Cercek A; Yaeger R; Segal NH; Ilson DH; Ku GY; Zehir A; Capanu M; Janjigian YY; Diaz LA; Maron SB
JAMA Netw Open; 2023 Feb; 6(2):e2254221. PubMed ID: 36729457
[TBL] [Abstract][Full Text] [Related]
2. Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer.
Lu Z; Zou J; Hu Y; Li S; Zhou T; Gong J; Li J; Zhang X; Zhou J; Lu M; Wang X; Peng Z; Qi C; Li Y; Li J; Li Y; Zou J; Du X; Zhang H; Shen L
JAMA Netw Open; 2019 Jul; 2(7):e197621. PubMed ID: 31339548
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer.
Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W
Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000
[TBL] [Abstract][Full Text] [Related]
4. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
5. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.
Coombs CC; Zehir A; Devlin SM; Kishtagari A; Syed A; Jonsson P; Hyman DM; Solit DB; Robson ME; Baselga J; Arcila ME; Ladanyi M; Tallman MS; Levine RL; Berger MF
Cell Stem Cell; 2017 Sep; 21(3):374-382.e4. PubMed ID: 28803919
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
[TBL] [Abstract][Full Text] [Related]
7. Associations Between Cancer Predisposition Mutations and Clonal Hematopoiesis in Patients With Solid Tumors.
Franch-Expósito S; Mehine M; Ptashkin RN; Bolton KL; Bandlamudi C; Srinivasan P; Zhang L; Goodell MA; Gedvilaite E; Menghrajani K; Sánchez-Vela P; Mandelker D; Comen E; Norton L; Benayed R; Gao T; Papaemmanuil E; Taylor B; Levine R; Offit K; Stadler Z; Berger MF; Zehir A
JCO Precis Oncol; 2023 Aug; 7():e2300070. PubMed ID: 37561983
[TBL] [Abstract][Full Text] [Related]
8. Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse.
Newell LF; Williams T; Liu J; Yu Y; Chen Y; Booth GC; Knight RJ; Goslee KR; Cook RJ; Leonard J; Meyers G; Traer E; Press RD; Fan G; Wang Y; Raess PW; Maziarz RT; Dunlap J
Transplant Cell Ther; 2021 Aug; 27(8):662.e1-662.e9. PubMed ID: 33901720
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors.
Ptashkin RN; Mandelker DL; Coombs CC; Bolton K; Yelskaya Z; Hyman DM; Solit DB; Baselga J; Arcila ME; Ladanyi M; Zhang L; Levine RL; Berger MF; Zehir A
JAMA Oncol; 2018 Nov; 4(11):1589-1593. PubMed ID: 29872864
[TBL] [Abstract][Full Text] [Related]
11. Clonal Hematopoiesis and Risk of Incident Lung Cancer.
Tian R; Wiley B; Liu J; Zong X; Truong B; Zhao S; Uddin MM; Niroula A; Miller CA; Mukherjee S; Heiden BT; Luo J; Puri V; Kozower BD; Walter MJ; Ding L; Link DC; Amos CI; Ebert BL; Govindan R; Natarajan P; Bolton KL; Cao Y
J Clin Oncol; 2023 Mar; 41(7):1423-1433. PubMed ID: 36480766
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer.
Lee KS; Lee CK; Kwon SS; Kwon WS; Park S; Lee ST; Choi JR; Rha SY; Shin S
Clin Chem Lab Med; 2024 Jan; 62(1):178-186. PubMed ID: 37435889
[TBL] [Abstract][Full Text] [Related]
14. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
[TBL] [Abstract][Full Text] [Related]
15. Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.
Boucai L; Falcone J; Ukena J; Coombs CC; Zehir A; Ptashkin R; Berger MF; Levine RL; Fagin JA
J Clin Endocrinol Metab; 2018 Nov; 103(11):4216-4223. PubMed ID: 30137527
[TBL] [Abstract][Full Text] [Related]
16. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
[TBL] [Abstract][Full Text] [Related]
18. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
20. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
